Gout and obesity: new trial tests Weight-Loss drug to lower uric acid

NCT ID NCT07326839

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the weight-loss drug orlistat to standard gout treatment helps obese patients lower uric acid levels and reduce gout attacks. 120 adults with gout and obesity will take either orlistat or a placebo for 24 weeks, along with diet and exercise advice. The main goal is to see how many reach a safe uric acid level, with secondary focus on weight loss and inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • General Hospital of Northern Theater Command, PLA

    Shenyang, Liaoning, 110016, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••